Rationale Infrahuman and human studies suggest that a determinant of the abuse potential of a drug is rate of onset of subjective effects. Objectives This study sought to determine if the rate of onset of subjective effects and abuse potential of alprazolam would be increased when administered via inhalation vs. the oral route. Methods Placebo, inhaled alprazolam (0.5, 1, and 2 mg), and oral alprazolam (1, 2, and 4 mg) were administered under double-blind, double-dummy conditions using a crossover design in 14 healthy participants with histories of drug abuse. Participant and observer ratings and behavioral and cognitive performance measures were assessed repeatedly during 9-h sessions. Results Both routes of administration produced orderly dose and time-related effects, with higher doses producing greater and longer-lasting effects. Onset of subjective effects following inhaled alprazolam was very rapid (e.g., 2 vs. 49 min after 2 mg inhaled vs. oral). On measures of abuse potential (e.g., liking and good effects), inhaled alprazolam was more potent, as evidenced by a leftward shift in the dose-response curve. Despite the potency difference, at the highest doses, peak ratings of subjective effects related to abuse potential (e.g., "drug liking") were similar across the two routes. On other measures (e.g., sedation and performance), the routes were equipotent. Conclusions The inhaled route of administration modestly increased the abuse potential of alprazolam despite significantly increasing its rate of onset. If marketed, the reduced availability and increased cost of inhaled alprazolam may render the societal risk of increased abuse to be low.
Introduction
It is widely believed that the abuse liability of a drug is determined, in part, by its speed of onset (as indicated by time to onset or time to maximum subjective effects). Increasing the speed of drug onset may increase the abuse potential of a drug by decreasing the interval between drug administration and the onset of subjective effects (i.e., the "rate hypothesis") (Gorelick 1998; Oldendorf 1992) . Anecdotally, many commonly abused drugs (e.g., cocaine and heroin) are preferentially administered using routes of administration that result in a rapid onset of effects such as intravenous injection, inhalation (e.g., smoking), and intranasal (e.g., snorting).
Consistent with the rate hypothesis, drug selfadministration studies in infrahuman subjects have shown that drugs are more reinforcing when administered intravenously vs. orally or intragastrically (Griffiths et al. 1985) . In studies examining different durations of cocaine infusions in rhesus monkeys, the rate of responding for a fixed dose of cocaine increased as infusion speed increased (Balster and Schuster 1973) . Based on these findings, it was proposed that the reinforcing effects of cocaine result from a joint function of dose and infusion rate. Other studies in rhesus monkeys demonstrated that more rapid infusions of cocaine were associated with an increased number of injections per session on a progressive ratio schedule (Woolverton and Wang 2004) . In a similar manner, in rhesus monkeys trained to self-administer nicotine, 24 h self-administration rates increased as the rate of drug delivery was increased (Wakasa et al. 1995) . In crabeating monkeys (Macaca irus), Kato et al. found that the threshold dose for producing cocaine and pentobarbital selfadministration decreased as infusion rate increased (Kato et al. 1987) . Taken together, these results indicate that in animal models, the reinforcing effects of drugs are increased by more rapid administration. While the precise mechanism(s) underlying this relationship are unclear, more rapid routes of administration typically result in a more rapid onset of drug effects and reduce the delay between self-administration and peak drug plasma levels. This reduces the delay between the response and the reinforcing stimulus, increasing its reinforcing efficacy.
Human studies in drug users have shown that when dose and duration of intravenous cocaine infusions are manipulated, drug liking (e.g., euphoria) is positively related to speed of infusion (Fischman and Schuster 1984) . In volunteers who use intravenous cocaine and heroin, subjective responses to identical doses of cocaine (but not hydromorphone) were greater when cocaine was administered more rapidly (Abreu et al. 2001) . A third study examining the effect of rate of infusion of intravenous cocaine in humans found that the rate of cocaine infusion affected both subjective and cardiovascular outcome measures. Furthermore, positive subjective effects (e.g., "good," "stimulated," and "like") were most affected by rate, even when controlling for dose. The study was unique in that it included variation of both cocaine dose and rate of infusion (Nelson et al. 2006) . In human opioid users, faster infusions of morphine produced greater positive subjective effects, drug effects, and plasma drug levels. The authors suggested that both the dose and rate of drug administration affect abuse liability (Marsch et al. 2001) .
Studies that have manipulated the rate of delivery of benzodiazepines and barbiturates in humans have shown that when administered as a single oral dose (that results in relatively rapid peak plasma levels) diazepam and pentobarbital are associated with greater increases in subjective effects related to abuse liability than when given as divided doses (which result in longer time-to-peak plasma levels) (de Wit et al. 1992 (de Wit et al. , 1993 . It is important to note that similar peak plasma levels of drug were obtained using each dosing regimen, albeit at different time points. Based on these results, the authors concluded that the rate at which blood levels of a drug increase is positively related to subjective effects associated with its abuse.
With respect to benzodiazepines, compounds that are rapidly absorbed are preferred to those with slower absorption rates (Griffiths et al. 1984) . For example, when comparing the effects of diazepam and oxazepam in sedative abusers, participants preferred diazepam over oxazepam and were willing to pay more for the former (Griffiths et al. 1984 ). This finding is consistent with diazepam's more rapid onset of subjective effects and comments from study participants that cited a rapid onset as a desirable feature of diazepam (Griffiths et al. 1984) . Along these same lines, extended release alprazolam was shown to have less potential for abuse than immediate release alprazolam (Mumford et al. 1995a) . In that study, the highest dose of extended release alprazolam (3 mg) failed to produce greater ratings of "good effects," "strength," and "liking" than the lowest dose of immediate release alprazolam (1 mg). It is notable that there were several instances where equivalent plasma concentrations of alprazolam were achieved between the two formulations, yet only the IR formulation affected subject ratings of drug effects. Based on these results, the authors suggested that the abuse liability of alprazolam is affected by both dose and release rate (Mumford et al. 1995a) . Alexza Pharmaceutical's Staccato® technology is a novel inhalation drug delivery system. The Staccato® system consists of a breath-actuated inhaler that incorporates a solid, thin film of drug on an inert metal substrate. By rapidly heating the metal substrate, the drug film is rapidly vaporized to form a highly pure aerosol. The Staccato® system has previously been shown to deliver drugs with intravenous-like pharmacokinetics (PK) in humans and canines, including a rapid onset of pharmacodynamic effects (Avram et al. 2007 (Avram et al. , 2009 (Avram et al. , 2013 Rabinowitz et al. 2004 Rabinowitz et al. , 2006 . For example, 1 mg of inhaled alprazolam produced peak plasma levels in 3.84 min (Alexza Pharmaceuticals 2014a, b) . Similarly, when Avram et al. (2013) administered zaleplon using the Staccato® system, peak sedative effects (measured with VAS) occurred about 3 min after dosing. This was in contrast to orally administered zaleplon for which peak pharmacodynamic effects occurred approximately 90 min after administration. Because increasing the rate of delivery of a drug may increase its abuse potential by increasing the speed of onset of drug effects, the purpose of the present study was to compare the abuse potential of inhaled alprazolam to an oral alprazolam preparation.
Methods
Study participants Participants were eight males and seven females with a history of sedative abuse or dependence without any other significant medical or psychiatric conditions. The study was conducted at the Behavioral Pharmacology Research Unit (BPRU) of the Johns Hopkins University School of Medicine. Participants gave their informed consent. The protocol and recruitment materials were approved by the University's Institutional Review Board. The study was conducted in accordance with the Declaration of Helsinki and registered at www.clinicaltrials.gov (NCT00603980). Participants were paid.
Participants were initially interviewed over the telephone. Eligible candidates were scheduled for an in-person screening. During in-person screenings, applicants underwent a physical exam and a medical history review. Participants completed a structured clinical interview for psychiatric conditions (Diagnostic and Statistical Manual-Version IV (DSM-IV)) and had their blood and urine collected for testing. An electrocardiogram was performed along with a drug screen, pregnancy test, alcohol breathalyzer test, and training on study assessments. Participants were required to meet the following entry criteria: (i) have a history of substance abuse or dependence (DSM-IV) on a commonly abused recreational drug (e.g., benzodiazepines, opioids, or cocaine), (ii) be age 18-55, (iii) report nontherapeutic use of barbiturates and/or benzodiazepines for their intoxicating effects at least once in the past year, (iv) be in good general health, (v) have a negative pregnancy test, (vi) have not participated in a clinical trial 30 days prior to screening, (vii) not taking CYP3A inhibitors or inducers, and (viii) have no history of acute or chronic pulmonary disease. Eligible participants visited BPRU up to three times per week on an outpatient basis.
Fifty-one participants signed the informed consent form. Twenty-five participated in the qualifying sessions, 15 completed the qualifying sessions, and 14 completed the study.
Qualifying sessions Before test sessions, volunteers completed two double-blind qualifying sessions to identify individuals who demonstrated greater liking for the effects of oral alprazolam relative to placebo.
During both qualifying sessions, participants swallowed four, band-sealed, size 0, orange, opaque, hard gelatin capsules at two time points. The first set of capsules was administered at the beginning of the session, and the second set was administered 1 h later, immediately before administration of inhaled Staccato® placebo (Alexza Pharmaceuticals, Mountain View CA). During the placebo session, both sets of capsules contained placebo (lactose). During the active (e.g., nonplacebo) qualifying session, the first set of capsules contained oral alprazolam (2 mg; Murty Pharmaceuticals, Lexington, KY) and the second set contained placebo. Active, inhaled drug was not administered during any qualifying session.
During the first qualifying session, half of the subjects received oral placebo and half of the subjects received oral alprazolam. Only participants who demonstrated greater liking for oral alprazolam vs. placebo (as determined by a difference of at least one point on the overall drug liking score on the end-of-day questionnaire) participated in test sessions.
Test sessions The timing of procedures for daily test sessions are summarized in Electronic supplementary material (ESM) Table 1 . Eligible subjects participated in up to three sessions per week. Sessions were separated by at least 48 h. Participants arrived at the research unit by 7:00 a.m. Before each session, participants performed a breathalyzer test and provided a urine sample that was tested for amphetamines, cocaine, barbiturates, benzodiazepines, and opiates. Participants who tested positive for alcohol or illicit drug use were not allowed to participate in that day's test session.
Responses to questionnaires were recorded on Macintosh computers (Apple, Cupertino, CA). When not completing an experimental task, participants were allowed to engage in recreational activities (e.g., playing games or reading).
During sessions, participants received one of seven different treatments under double-blind conditions: oral alprazolam (1, 2, and 4 mg), inhaled alprazolam (0.5, 1, and 2 mg), or placebo. The sequence and order of doses were counterbalanced across participants, and each participant received all treatments in a crossover design. The crossover sequences were determined according to a seven-treatment, seven-period Latin Square of Williams design balanced for first-order carryover effects. The circular lights, digit-symbolsubstitution task (DSST), subjective effects questionnaire, observer-rated questionnaire, and drug effects questionnaire, were completed before capsule administration. Capsules were administered after baseline assessments. One hour later, a second set of capsules (always placebo) was administered along with inhaled Staccato® placebo or Staccato® alprazolam. The timing of the drug administrations was scheduled to obscure from participants and staff the differences in rates of onset and to preserve the study blind. To reduce possible taste discrimination between placebo and inhaled alprazolam, participants were given a rapidly dissolving, intensely flavored breath mint strip after each capsule set.
Drug effect questionnaire This previously described participant-rated questionnaire (Mumford et al. 1995b; Evans et al. 1990; Reissig et al. 2012 ) consisted of 5-point rating scales of drug strength, good effects, bad effects, high, and rush and a 9-point, bipolar drug-liking rating scale ("dislike very much," "dislike quite a bit," "dislike somewhat," "dislike, but not very much," "neutral or no effect," "like, but not very much," "like somewhat," "like quite a bit," and "like very much"). This task was completed before and at 2 min, 5 min, 10 min, 20 min, 30 min, 45 min, 60 min, 62 min, 65 min, 70 min, 80 min, 90 min, 105 min, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, and 9 h after administration of the first capsules. Sedation (subjective effects questionnaire) This previously described participant-rated questionnaire (Rush et al. 1999) consisted of 13 adjectives thought to be sensitive to sedative drugs (e.g., "Do you feel sleepy?"). Participants were instructed to rate how they felt on a 5-point scale ("not at all," "a little bit," "moderately," "quite a bit," and "extremely"). Ratings were summed across the 13 items and expressed as a total score. This questionnaire was completed before and 30 min, 60 min, 90 min, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, and 9 h after the first capsule administration.
Pharmacological class questionnaire This previously described participant-rated questionnaire (Rush et al. 1999) listed descriptive titles and examples of 12 classes of psychoactive drugs, including "blank or placebo" and "other." Participants were instructed to choose the option that they believed most closely represented the drug they received that day. This questionnaire was completed 9 h after the first capsule administration.
End-of-day questionnaire For this previously described questionnaire (Carter et al. 2006; Rush et al. 1999) , participants rated the overall effect of the drug they received that day. Subjects rated the overall strength of the drug effect, overall good effects, overall bad effects, and the degree to which they would like to take the drug again on a 5-point scale. Subjects rated their overall drug liking on a bipolar, 9-point scale, estimated the amount of money the drug would be worth on the street, and estimated the amount of money they would pay to receive that drug again. This questionnaire was completed 9 h after administration of the first capsules.
Observer-rated measures This previously described questionnaire (Rush et al. 1999 ) consisted of eight items. A staff member rated each participant on: sedation/sleepiness, locomotor and nonlocomotor muscle relaxation, posture, slurred speech, confusion/disorientation, stimulation/arousal, and strength of drug effect. Observers rated each dimension on a 5-point scale from 0 (normal) to 4 (very strong drug effect). This task was completed before and at 10 min, 20 min, 30 min, 45 min, 60 min, 70 min, 80 min, 90 min, 105 min, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, and 9 h after administration of the first capsules.
Circular lights This 1-min psychomotor task, described previously (Mumford et al. 1995a, b) , required participants to press a series of 16 buttons as rapidly as possible in response to a random sequence of illuminated lights. The score was the number of correct button presses during the 1-min trial. Timing of this assessment was the same as that for the observer-rated measures.
Digit-symbol-substitution task This task was a computer version of the DSST (McLeod et al. 1982) , a 90-s trial that required participants to use a numeric keypad to type keys corresponding to a geometric pattern displayed on a computer screen. The score was the number of correct patterns entered during the 90-s trial. Timing of this task was the same as that for the observer-rated measures.
Word recall task This task consisted of a word encoding phase followed 10 min later by a word recall test. For the encoding phase, participants were presented with 16 words that appeared on a computer screen one at a time. Participants classified each word as artificial (i.e., manmade) or natural by clicking a button on the computer screen. Participants were informed that their memory for these words would be tested later in the session. In the recall test, participants were instructed to write down as many words as possible from the list of words they had classified as artificial or natural 10 min earlier.
The score was the number of words (out of 16) correctly recalled. For details, see (Carter et al. 2009 ). This task was given twice. The first time corresponded to the expected time of peak effect for inhaled alprazolam (encoding occurred 10 min after inhalation administration, which was 70 min after administration of the first capsules). The second time corresponded to the expected time of peak effects for the oral administration (encoding occurred 2 h after administration of the first capsules, which was 1 h after inhalation administration). In both cases, recall occurred 10 min after encoding.
Data analysis
Time course data were analyzed with repeated-measure regressions using SAS PROC MIXED. Drug condition and time were included in the model. Planned comparison t tests were conducted between placebo and active doses at each time point.
For the 9-point, bipolar drug-liking scales (the end-of-day and drug effect questionnaires), data were divided into separate measures of "liking" and "disliking." For purposes of data analysis, ratings of liking were assigned a score of 0 if a participant indicated disliking. Conversely, ratings of disliking were assigned a score of 0 if a participant indicated liking. For participant-and observer-rated measures assessed at multiple time points, peak effect for each session was defined as the maximum value recorded within 9 h after administration of the first set of capsules. For psychomotor performance and cognitive assessment measures (i.e., DSST, word recall, and circular lights), the peak effect for each session was defined as the minimum value scored during the 9 h. Data from the peak effect calculations and from assessments that were completed once per session were analyzed using SAS PROC MIXED (SAS Institute, Cary, NC). Fisher's least significant difference (LSD) post hoc tests were used to compare drug conditions. Data from the word recall task were analyzed using SAS PROC MIXED with Fisher's LSD post hoc tests to compare all conditions within each time point. For all analyses and statistical tests, p<0.05 was considered significant.
For purposes of summarizing drug effect time course, means and SEMs were calculated at each time point for the 15 measures (shown in Tables 1 and 2; ESM Table 2 ) that were assessed at multiple time points (six participant ratings, seven observer ratings, and the circular lights and DSST). Time-to-onset was defined as the first time point after drug administration that was significantly different from placebo. Time-to-peak effect was defined as the time point corresponding to the peak of the group data. Time to offset was defined as the time point after the last significant difference from placebo.
Relative potency between oral and inhaled alprazolam was calculated according to the methods of Finney on measures assessed at a single time point and on peak effects for measures assessed at multiple time points. Tests for linearity, parallelism, preparation (route) differences, and significant regression (i.e., significant dose effects) were conducted. Relative potency estimates are not reported for variables that did not meet these validity criteria.
For all analyses and statistical tests, p <0.05 was considered significant.
Data from the pharmacological class questionnaire were calculated as the percentage of participants that chose each drug class for each of the seven drug conditions. Figure 1 shows time course data for inhaled and oral alprazolam on two participant-rated measures reflecting abuse potential (liking and good effects) and on two measures of behavioral performance (circular lights and DSST). Both routes of administration produced orderly, dose and timerelated effects, with higher doses producing greater and longer-lasting effects.
Results

Time course
Inspection of the data indicated that the onset of drug effects after inhaled alprazolam was very rapid and generally more rapid than after oral administration. For example, at the same dose of alprazolam (2 mg), the mean (SEM) time to onset of drug effects across 15 participant-rated, observerrated, and performance measures (see "Data analysis" and ESM Table 2 ) was 11.3 min (2.3) after inhaled administration vs. 62.8 min (3.9) after oral administration (ESM Table 2 ). These onset times tended to be shortest for the five participant ratings assessing positive subjective effects related to abuse potential (drug effects questionnaire ratings of strength, liking, good effects, high, and rush): a mean of 2.0 min (no variation) after inhaled vs. 49.4 min (range 30 to 65) after oral administration.
As shown in Fig. 1 , for ratings of liking and good effects, the two highest doses of inhaled alprazolam (1 and 2 mg) were significantly different from placebo at the first time point (2 min after inhalation) and reached 80 to 90 % of peak mean rating by the second time point (5 min).
Likewise, inspection of the data showed that time-to-peak effect was generally shorter after inhaled vs. oral administration. For example, for the 2 mg dose of alprazolam across the 15 measures noted above, the mean (SEM) time-to-peak effect was 51.7 min (14.3) after inhaled vs. 120.1 min (5.9) after oral administration (ESM Table 2 ).
The time to offset of participant-rated drug effects was only somewhat shorter after inhaled vs. oral administration. For the 2 mg dose of alprazolam across the 15 measures noted above, the mean (SEM) time to offset was 216.0 min (19.2) after inhaled vs. 262.0 min (19.0) after oral administration (ESM Table 2 ).
Participant-rated measures related to abuse potential Table 1 and Fig. 2 summarize participant ratings of measures of drug strength and various measures related to abuse potential that were assessed throughout the session (peak effects) or at the end of the session. Strength ratings are reported here because these questions were asked in the context of ratings of abuse potential. Both oral and inhaled alprazolam produced doserelated and significant effects on most items. Inhaled alprazolam was generally more potent than oral alprazolam (i.e., the dose effect function was shifted to the left), and valid relative potency estimates for inhaled vs. oral alprazolam were calculated for 10 of 11 measures. The mean relative potency difference was 2.01 (ranging from 1.53 to 2.94). Consistent with these potency differences, at identical doses (i.e., comparing 1 mg oral vs. inhaled and 2 mg oral vs. inhaled), inhaled alprazolam almost always (21 of 22 comparisons) produced greater effects than oral alprazolam. These effects were generally not statistically significant except that on the end-of-day questionnaire, 1 mg of inhaled alprazolam produced increases on overall liking and overall good effects that were significantly greater than 1 mg of oral alprazolam.
Peak participant ratings of bad effects were modestly, but significantly, increased relative to placebo after all three doses of oral alprazolam, but not increased by any dose of inhaled alprazolam. The mean (SEM) peak rating of bad effects after the highest dose of oral alprazolam (4 mg) was 1.07 (0.27) and significantly higher than all three doses of inhaled alprazolam. However, participant ratings of drug disliking (peak and end of day) and end-of-day ratings of bad effects were not significantly different across experimental conditions. Word task encoding at the 2nd time point occurred 2 h after oral capsules and 1 h after inhalation; recall occurred 10 min later f Relative potency could not be calculated due to missing data Participant and observer ratings and performance measures Table 2 and Fig. 3 summarize other participantrated, observer-rated, and performance measures. Similar to the participant ratings related to abuse potential, oral and inhaled alprazolam produced dose-related and significant effects on most of these measures. In contrast to the abuse potential measures, inhaled alprazolam was not reliably more potent than oral alprazolam. For most of these measures, inspection of the data and relative potency calculations indicated that the potency of inhaled and oral alprazolam were similar (Fig. 3) . Furthermore, for the five measures for which valid relative potency measures could be calculated, the mean relative potency was only 1.36. Relative to placebo, both inhaled and oral alprazolam produced dose-related impairment on the word recall task, as demonstrated by a decrease in the number of words recalled Fig. 1 Time course of effects of inhaled alprazolam (left) and oral alprazolam (right) on participant ratings of drug liking and good effects from the drug effect questionnaire (top 2 rows) and performance on the circular lights task and the digit-symbolsubstitution task (bottom 2 rows). Y-axes: mean participant rating of liking and good effects (0-to 4-point scale), mean score on the circular lights task, and mean trials correct on the digit-symbolsubstitution task. X-axes: left, time in minutes after inhaled administration; right, time in minutes after the first set of oral capsules were administered; 0 shows the pre-administration time point. Data symbols show means (N=14). Filled symbols indicate values that are significantly different from the corresponding placebo value at the same time point (p<0. 05, planned comparisons) at both time points, with no differences between the two occasions the task was administered (Table 2) . Criteria were not fulfilled for calculation of valid relative potency analyses.
Pharmacological class questionnaire As shown in Table 3 , placebo was correctly rated as placebo by 79 % of study participants. With increasing doses of inhaled and oral alprazolam, there was a generally increasing frequency of rating drug conditions as being active (i.e., not placebo) and being either a barbiturate/sleeping medication or a benzodiazepine, with 57 to 71 % of subjects selecting either class across the two highest doses of both formulations.
Discussion
The objective of this study was to assess the abuse potential of inhaled alprazolam (delivered via Staccato® technology) relative to oral alprazolam. Both infrahuman and human studies provide evidence for the belief that the abuse potential of a reinforcing drug is increased by increasing its speed of onset. However, the current study determined that, despite a much more rapid time of onset, the abuse potential of inhaled alprazolam is only modestly greater relative to the oral formulation.
As expected, inhaled alprazolam resulted in a much more rapid onset of drug effects, with significant subjective effects detected at the first time point after administration (2 vs. 49 min after 2 mg of inhaled and oral alprazolam, respectively). Likewise, inhaled alprazolam generally resulted in a shorter time-to-peak subjective and behavioral effects (52 vs. 120 min after 2 mg inhaled and oral alprazolam, respectively). On participant ratings most relevant to abuse potential (e.g., liking and good effects), inhaled alprazolam was generally more potent than oral alprazolam, as evidenced by a leftward shift in the dose-response curve (Table 1 ; Fig. 2 ). This is in contrast to the absence of potency differences across various Fig. 3 ). For the abuse potential measures, valid relative potency differences, which averaged 2.01, were calculated for 10 of the 11 abuse potential measures (Table 1) . Consistent with the relative Fig. 3 Effects of placebo (circles), inhaled alprazolam (squares), and oral alprazolam (triangles) on observer ratings, participant ratings, and performance measures that do not specifically assess abuse potential. Left, peak effects of observer ratings of locomotor relaxation, confusion/ disorientation, and slurred speech. Right, peak effects of participant ratings of sedation and performance on the circular lights and digit-symbol-substitution tasks. Y-axes: observer ratings (0-to 4-point scale); participant rating of sedation (0-to 52-point scale); circular lights task score and digit-symbol-substitution task trials correct; X-axes: dose in milligrams; P placebo. Data points show means (N=14), brackets show plus or minus 1 SEM. Filled symbols indicate values that are significantly different from placebo; data points that do not share a common letter are significantly different from one another (p<0.05, Fisher's LSD) potency differences between inhaled and oral alprazolam, at the same absolute dose, inhaled alprazolam almost always produced numerically greater effects than oral alprazolam. Although these effects were generally not statistically significant, the consistency of the findings across the different measures of abuse potential suggests that at identical doses, inhaled alprazolam has an increased abuse potential relative to the oral formulation, albeit to a moderate degree. However, despite the increase in potency, the highest values produced by the highest dose of each formulation (e.g., 4 mg of oral and 2 mg inhaled) did not differ on the majority of abuse potential measures examined. Based on anecdotal reports suggesting large increases in abuse potential with rapidly administered drugs (e.g., intravenous or smoked cocaine), it might have been expected that changing the route of alprazolam administration from oral to inhaled would result in an increased abuse potential of many orders of magnitude. It did not.
It is of interest to consider the implications of the above findings for predicting the actual abuse of inhaled vs. oral alprazolam. We hypothesize that given equivalent availability and cost, inhaled alprazolam would engender more abuse. However, the Staccato® delivery device permits administration of only a single dose of drug. It seems likely that, if marketed, Staccato® alprazolam would cost more, and the number of dosage units dispensed would be substantially fewer relative to the oral dosage form. If these assumptions are correct, the amount of Staccato® alprazolam available for diversion and abuse would be quite low.
In contrast to measures reflecting abuse potential, the comparison of inhaled vs. oral routes on participant-rated sedation, observer-rated behavioral effects, and measures of psychomotor and cognitive performance were not generally associated with potency differences ( Fig. 3 ; Table 2 ). For example, although both inhaled and oral alprazolam produced doserelated decreases in performance on the circular lights and DSST, similar doses produced similar decrements in performance (e.g., 2 mg inhaled produced effects comparable to 2 mg oral). When examined in the context of the abuse potential assessments, it may be that increasing the rate of onset of a drug affects some types of measures (e.g., abuse potential) and not others (e.g., psychomotor effects).
It is widely believed that the rate of onset of subjective effects is an important determinant of the abuse potential of a drug, and it is often presumed that the primary determinant of rate of onset is the speed of drug delivery to plasma or brain. However, other PK factors may play a significant role including peak plasma levels (C max ), absorption, and overall drug exposure (area under the curve (AUC)). Thus, a major limitation of the current study was the lack of assessment of drug plasma levels following administration. We cannot rule out the possibility that the differences in abuse potential measures (or lack thereof) are due to differences in absorption, peak drug plasma levels, or other PK parameters (e.g., C max and T max ).
However, prior clinical assessments of Staccato® alprazolam have demonstrated that the 1-mg dose produces peak plasma levels of drug in 3.84 min (Alexza Pharmaceuticals 2014a, b), a finding that is consistent with the rapid onset of drug effects (∼2 min; ESM Table 2 ) observed in the present study. These data are consistent with clinical and preclinical PK analyses of several different drug substances delivered via the Staccato® system. These studies have generated consistent results, with peak plasma levels observed 3-5 min after inhalation, regardless of the drug substance administered (Alexza Pharmaceuticals 2014c; Avram et al. 2007 Avram et al. , 2009 Avram et al. , 2013 Macleod et al. 2012; Rabinowitz et al. 2004 Rabinowitz et al. , 2006 Spyker et al. 2010) . Another limitation of the present study is the relatively small sample size (N=14). Future studies designed to differentiate among different routes of administration should use larger samples.
In contrast to the inhalable formulation, the effects of orally administered alprazolam peaked around 120 min and produced dose-related sedation, findings consistent with its PK profile (Greenblatt and Wright 1993; Smith et al. 1984) , and prior studies examining the pharmacodynamics and abuse potential of immediate release alprazolam (Mumford et al. 1995a) .
The novelty of the Staccato® drug delivery system may also have affected the study results. For most benzodiazepine users, the oral route of administration is the most common method of recreational use (Roset et al. 2001) . The unfamiliarity with the Staccato® system might have affected its abuse potential, although the pharmacological class questionnaire results suggest that volunteers identified each formulation as a sedative-like drug (Table 3) .
In this study, we demonstrated that despite a marked difference in rates of onset, differences in abuse liability measures between inhaled and oral alprazolam were modest. The modest increase in abuse liability resulting from the rapid onset of drug effects after inhaled administration via the Staccato® system must be weighed against possible therapeutic advantages. Currently approved immediate release alprazolam tablets reach peak plasma concentrations 1 to 2 h after administration. Oral spray products containing non-benzodiazepine compounds (e.g., ZolpiMist™) also produce peak plasma concentrations about an hour after administration (Neubauer 2010) . The relatively slow onset of effects after the oral administration of drugs precludes their use in situations in which rapid effects are desired (e.g., treating an acute panic attack in a public setting). Administration systems that result in intravenous-like onset of drug effects may offer significant therapeutic advantages in therapeutic areas in which rapid drug onset is desirable, such as in the treatment of panic attacks, migraine headaches, epileptic seizures, and the management of acute psychosis.
